BNBX

BNBX is no longer an operating business you can underwrite — it is a failed testing/synthetic-DNA company (LineaRx/ADCL) that gutted its workforce in three successive 2025 reductions (20%, then 27%, then ~60%) and, per the MD&A, has re-tooled itself into a 'digital asset treasury' that will use financing proceeds to accumulate BNB, the Binance-ecosystem token, for staking/DeFi yield. The core business has already imploded: revenue cratered from $18.2M (FY2022) to $2.11M (FY2024) to a flat $2.14M (FY2025), while the FY2025 net loss ballooned to -$15.2M with a -750.9% operating margin and $6.02M of R&D against $839K of gross profit. This is not a company being valued on its 0.7x P/S; that ratio is a meaningless artifact of a near-dead legacy segment.

The balance sheet and structure compound the problem. Total assets fell 65% to $4.44M, equity fell 75% to $2.30M, cash fell 71% to $1.67M, and the accumulated deficit sits at -$379M — this entity has destroyed capital for years. Operating cash flow was -$12.2M, so absent the October 2025 private placement ($26.8M in cash/crypto, plus up to $30.8M more from warrant exercises) it was running out of money. That capital raise is the whole story now, and it means enormous dilution and warrant overhang against just 4.37M shares (themselves the residue of a ~92% share-count reduction, i.e. a large reverse split that produced the surreal -$134.23 diluted EPS). The filing explicitly warns management may spend proceeds buying more BNB or on repurchases in ways holders 'may not agree' with.